NASDAQ:CYAD

Celyad Oncology - CYAD Stock Forecast, Price & News

$1.35

0.00 (0.00%)

(As of 01/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.32
▼
$1.49
50-Day Range: $0.49
▼
$2.37
52-Week Range: $0.46
▼
$3.63

Volume: 78,929 shs
Average Volume: 4.53 million shs
Market Capitalization: $30.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.78

Institutional Ownership

About Celyad Oncology (NASDAQ:CYAD) Stock

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

CYAD Stock News Headlines

January 18, 2023 | ca.finance.yahoo.com

Celyad Oncology SA (CYAD)

January 17, 2023 | benzinga.com

Thinking about buying stock in Celyad Oncology, Calyxt, IQIYI, Vinco Ventures, or Carvana?

January 31, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

December 29, 2022 | finance.yahoo.com

Celyad Oncology Completely Shifts To Preclinical Stage, Pulls Plug On Only Human Trial Asset

December 21, 2022 | tmcnet.com

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness

December 21, 2022 | markets.businessinsider.com

Celyad Oncology To Discontinue CYAD-211 Clinical Program In Multiple Myeloma

December 21, 2022 | seekingalpha.com

Celyad stock slumps 25% as blood cancer drug CYAD-211 gets axed in strategic review

December 21, 2022 | finance.yahoo.com

Celyad Oncology Provides an Update on Its Strategic Business Model, Continuing to Focus on Opportunities to Fully Harness the True Potential of Its Proprietary Technology Platforms and Intellectual Property

January 31, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

November 11, 2022 | reuters.com

Celyad Oncology SA

November 10, 2022 | finance.yahoo.com

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

October 12, 2022 | finance.yahoo.com

Celyad Oncology Provides Strategic Update

September 20, 2022 | finance.yahoo.com

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

August 5, 2022 | seekingalpha.com

Celyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call Transcript

August 1, 2022 | nasdaq.com

Celyad: FDA Lifts Clinical Hold On CYAD-101-002 Phase 1b Trial

August 1, 2022 | markets.businessinsider.com

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial

August 1, 2022 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

August 1, 2022 | finance.yahoo.com

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

July 28, 2022 | finance.yahoo.com

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

July 19, 2022 | seekingalpha.com

Celyad: Probably Still Top-Notch In Oncology

June 24, 2022 | finance.yahoo.com

Celyad Oncology Announces Leadership Updates

May 25, 2022 | finance.yahoo.com

Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know

May 17, 2022 | finance.yahoo.com

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

May 5, 2022 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

May 5, 2022 | seekingalpha.com

Celyad Oncology reports Q1 results

May 5, 2022 | finance.yahoo.com

CORRECTING AND REPLACING: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

May 5, 2022 | finance.yahoo.com

CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

CYAD Company Calendar

Today: 1/31/2023
Next Earnings (Estimated): 3/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CYAD
CUSIP: N/A
CIK: 1637890
Web: www.celyad.com
Phone: (210) 039-4100
Fax: 321-039-4141
Employees: 95
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.78
High Stock Price Forecast: $2.78
Low Stock Price Forecast: $2.78
Forecasted Upside/Downside: +105.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 1.71
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 3,049.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.29 per share
Price / Book: 0.59

Miscellaneous

Outstanding Shares: 22,590,000
Free Float: 22,382,000
Market Cap: $30.50 million
Optionable: Not Optionable
Beta: 1.38

Key Executives

Michel E. Lussier
Chief Executive Officer & Executive Director

David Georges
Vice President-Finance & Administration

Eytan Breman
Director-Research & Development

Frederic Lehmann
VP-Clinical Development & Medical Affairs

David Gilham
Chief Scientific Officer

Key Competitors

View All Competitors

CYAD Stock - Frequently Asked Questions

Should I buy or sell Celyad Oncology stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celyad Oncology in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CYAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYAD, but not buy additional shares or sell existing shares.
View CYAD analyst ratings or view top-rated stocks.
What is Celyad Oncology's stock price forecast for 2023?: 2 analysts have issued 1 year price objectives for Celyad Oncology's shares. Their CYAD share price forecasts range from $2.78 to $2.78. On average, they expect the company's share price to reach $2.78 in the next year. This suggests a possible upside of 91.7% from the stock's current price.
View analysts price targets for CYAD or view top-rated stocks among Wall Street analysts.
How have CYAD shares performed in 2023?: Celyad Oncology's stock was trading at $0.4929 at the beginning of the year. Since then, CYAD shares have increased by 194.2% and is now trading at $1.45.
View the best growth stocks for 2023 here.
When is Celyad Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our CYAD earnings forecast.

What other stocks do shareholders of Celyad Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).
When did Celyad Oncology IPO?: (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
What is Celyad Oncology's stock symbol?: Celyad Oncology trades on the NASDAQ under the ticker symbol "CYAD."
How do I buy shares of Celyad Oncology?: Shares of CYAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Celyad Oncology's stock price today?: One share of CYAD stock can currently be purchased for approximately $1.45.
How much money does Celyad Oncology make?: Celyad Oncology (NASDAQ:CYAD) has a market capitalization of $32.76 million and generates $10,000.00 in revenue each year.
How can I contact Celyad Oncology?: Celyad Oncology's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The official website for the company is www.celyad.com. The company can be reached via phone at (210) 039-4100 or via fax at 321-039-4141.

This page (NASDAQ:CYAD) was last updated on 1/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial